High-dose ursodeoxycholic acid in primary sclerosing cholangitis: A 5-year multicenter, randomized, controlled study

Gastroenterology

Volumn 129, Issue 5, 2005, Pages 1464-1472

  Olsson, Rolf ^a   Boberg, Kirsten M ^b   Schaffalitsky De Muckadell, Ove ^c   Lindgren, Stefan ^d   Hultcrantz, Rolf ^e   Folvik, Geir ^f   Bell, Helge ^g   Gangsøy Kristiansen, Magnhild ^c   Matre, Jon ^h   Rydning, Andreas ⁱ   Wikman, Ola ^j   Danielsson, Åke ^k   Sandberg Gertzén, Hanna ^l   Ung, Kjell Arne ^c   Eriksson, Anders ^a   Lööf, Lars ^m   Prytz, Hanne ^d   Marschall, Hanns Ulrich ^e   Broomé, Ulrika ^e  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c University Hospital MAS ^*  (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f Helse Bergen   (Norway)

^g AKER UNIVERSITY HOSPITAL   (Norway)

^h Vest Agder Sykehus   (Norway)

ⁱ AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^j STOCKHOLM SÖDER HOSPITAL   (Sweden)

^k UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^l ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^m CENTRAL HOSPITAL   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; PLACEBO; URSODEOXYCHOLIC ACID;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; BACKACHE; BILE DUCT CARCINOMA; BODY WEIGHT; BREAST CARCINOMA; CAUSE OF DEATH; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MEGADOSE; FEMALE; FEVER; FLATULENCE; FOLLOW UP; GASTROENTEROLOGY; HEALTH SURVEY; HUMAN; INDIGESTION; LIVER FAILURE; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT OUTCOME; URTICARIA;

EID: 27744583768     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2005.08.017     Document Type: Article

References (35)

1. R. Olsson, A. Danielsson, G. Jarnerot, E. Lindstrom, L. Loof, P. Rolny, B.O. Ryden, C. Tysk, S. Wallerstedt Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis Gastroenterology 100 1991 1319 1323
2. E. Schrumpf, K.M. Boberg Epidemiology of primary sclerosing cholangitis (review) Best Pract Res Clin Gastroenterol 15 2001 553 562
3. U. Broome, R. Olsson, L. Loof, G. Bodemar, R. Hultcrantz, A. Danielsson, H. Prytz, H. Sandberg-Gertzen, S. Wallerstedt, G. Lindberg Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis Gut 38 1996 610 615
4. C.Y. Ponsioen, S.M. Vrouenraets, W. Prawirodirdjo, R. Rajaram, E.A. Rauws, C.J. Mulder, J.B. Reitsma, S.H. Heisterkamp, G.N. Tytgat Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population Gut 51 2002 562 566
5. A. Bergquist, A. Ekbom, R. Olsson, D. Kornfeldt, L. Loof, A. Danielsson, R. Hultcrantz, S. Lindgren, H. Prytz, H. Sandberg-Gertzen, S. Almer, F. Granath, U. Broome Hepatic and extrahepatic malignancies in primary sclerosing cholangitis J Hepatol 36 2002 321 327
6. K. Lindor Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group Ursodiol for primary sclerosing cholangitis N Engl J Med 336 1997 691 695
7. S. Ewerth, B. Angelin, K. Einarsson, K. Nilsell, I. Bjorkhem Serum concentrations of ursodeoxycholic acid in portal venous and systemic venous blood of fasting humans as determined by isotope dilution-mass spectrometry Gastroenterology 88 1985 126 133
8. J.E. Ware Jr, C.D. Sherbourne The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection Med Care 30 1992 473 483
9. R. Poupon, Y. Chrétien, R.E. Poupon, F. Ballet, Y. Calmus, F. Darnis Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1 1987 834 836
10. H. Hayashi, T. Higuchi, H. Ichimiya, N. Hishida, N. Sakamoto Asymptomatic primary sclerosing cholangitis treated with ursodeoxycholic acid Gastroenterology 99 1990 533 535
11. O. Chazouillères, R. Poupon, J.-P. Capron, E.-H. Methman, D. Dhumeaux, M. Amouretti, P. Couzigou, D. Labayle, J.-C. Trinchet Ursodeoxycholic acid for primary sclerosing cholangitis J Hepatol 11 1990 120 123
12. C.B. O'Brien, J.R. Senior, R. Arora-Mirchandani, A.K. Batta, G. Salen Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis a 30-month pilot study Hepatology 14 1991 838 847
13. U. Beuers, U. Spengler, W. Kruis, Ü. Aydemir, B. Wiebecka, W. Heldwein Ursodeoxycholic acid for treatment of primary sclerosing cholangitis a placebo-controlled trial Hepatology 16 1992 707 714
14. A. Stiehl, S. Walker, L. Stiehl, G. Rudolph, W.J. Hofmann, L. Thielmann Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period J Hepatol 20 1994 57 64
15. N. De Maria, A. Colantoni, E. Rosenbloom, D.H. Van Thiel Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period Hepatogastroenterology 43 1996 1472 1479
16. H.J.F. Van Hoogstraten, F.H.J. Wolfhagen, P.C. van de Meeberg, H. Kuiper, G.A.J.J. Nix, M.C.J.M. Becx Ursodeoxycholic acid therapy for primary sclerosing cholangitis results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses J Hepatol 29 1998 417 423
17. S.A. Mitchell, D.S. Bansi, N. Hunt, K. von Bergmann, K.A. Fleming, R.W. Chapman A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis Gastroenterology 121 2001 900 907
18. D.M. Harnois, P. Angulo, R.A. Jorgensen, N.F. LaRusso, K.D. Lindor High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis Am J Gastroenterol 96 2001 1558 1562
19. L. Okolicsanyi, M. Groppo, A. Floreani, A.M. Morselli-Labati, A.G. Rusticali, A. Battocia Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid results of a retrospective Italian multicentre survey Dig Liver Dis 35 2003 325 331
20. C. Schramm, P. Schirmacher, I. Helmereich-Becker, M. Manns Combined therapy with azathioprine, prednisolone and ursodiol in patients with primary sclerosing cholangitis. A case series Ann Intern Med 131 1999 943 946
21. R.K. Sterling, J.J. Salvatori, V.A. Luketic, A.J. Sanyal, A.S. Fulcher, R.T. Stravitz, M.J. Contos, A.S. Mills, M.L. Shiffman A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis Aliment Pharmacol Ther 20 2004 943 949
22. M.A. Färkkilä, A.L. Karvonen, H. Nurmi, H. Nuutinen, P. Pikkarainen, M. Taavitsainen, P. Kärkkäinen Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis a randomized placebo-controlled trial Hepatology 40 2004 1379 1386
23. A. Stiehl, G. Rudolph, P. Sauer, C. Benz, W. Stremmel, S. Walker Efficacy of ursodeoxycholic acid treatment and endoscopic dilatation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study J Hepatol 26 1997 56 61
24. R. Olsson, I. Hagerstrand, U. Broome, A. Danielsson, G. Jarnerot, L. Loof, H. Prytz, B.O. Ryden, S. Wallerstedt Sampling variability of percutaneous liver biopsy in primary sclerosing cholangitis J Clin Pathol 48 1995 933 935
25. B. Brandsaeter, U. Broome, H. Isoniemi, S. Friman, B. Hansen, E. Schrumpf, A. Oksanen, B.G. Ericzon, K. Hockerstedt, H. Makisalo, R. Olsson, M. Olausson, P. Kirkegaard, K. Bjoro Liver transplantation for primary sclerosing cholangitis in the Nordic countries outcome after acceptance to the waiting list Liver Transpl 9 2003 961 969
26. E. Bjornsson, J. Lindqvist-Ottosson, M. Asztely, R. Olsson Dominant strictures in patients with primary sclerosing cholangitis Am J Gastroenterol 99 2004 502 508
27. D.S. Pardi, E.V. Loftus Jr, W.K. Kremers, J. Keach, K.D. Lindor Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis Gastroenterology 124 2003 889 893
28. B.Y. Tung, M.J. Emond, R.C. Haggitt, M.P. Bronner, M.B. Kimmey, K.V. Kowdley, T.A. Brentnall Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis Ann Intern Med 134 2001 89 95
29. U. Sjoqvist, B. Tribukait, A. Ost, C. Einarsson, L. Oxelmark, R. Lofberg Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy a prospective, double-blind, randomized controlled pilot study Anticancer Res 24 2004 3121 3127
30. L. Serfaty, A. De Leusse, O. Rosmorduc, B. Desaint, J.F. Flejou, O. Chazouilleres, R.E. Poupon, R. Poupon Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis an observational study Hepatology 38 2003 203 209
31. K. Oyama, G. Shiota, H. Ito, Y. Murawaki, H. Kawasaki Reduction of hepatocarcinogenesis by ursodeoxycholic acid in rats Carcinogenesis 23 2002 885 892
32. P.M. Battezzati, M. Zuin, A. Crosignani, M. Allocca, P. Invernizzi, C. Selmi, E. Villa, M. Podda Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis a double-blind, placebo-controlled trial on symptomatic patients Aliment Pharmacol Ther 15 2001 1427 1434
33. C. Gluud, E. Christensen Ursodeoxycholic acid for primary biliary cirrhosis (review) Cochrane Database Syst Rev 2002 CD000551
34. W.R. Kim, K.D. Lindor, M. Malinchoc, J.L. Petz, R. Jorgensen, E.R. Dickson Reliability and validity of the NIDDK-QA instrument in the assessment of quality of life in ambulatory patients with cholestatic liver disease Hepatology 32 2000 924 929
35. Z.M. Younossi, N. Boparai, L.L. Price, M.L. Kiwi, M. McCormick, G. Guyatt Health-related quality of life in chronic liver disease the impact of type and severity of disease Am J Gastroenterol 96 2001 2199 2205